Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Intradural artery dilation during experimentally induced migraine attacks

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Neck pain and headache after whiplash injury: a systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  1. CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The chronobiology of migraine: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  3. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Migraine attacks are often preceded by premonitory symptoms (PS) that may be triggered pharmacologically. We investigated the incidence of PS after administration of calcitonin gene-related peptide (CGRP) or pituitary adenylate cyclase-activating peptide-38 (PACAP38) in patients with migraine without aura (MO) who reported and did not report migraine-like attacks induced by these pharmacological triggers. In addition, we investigated the association between PS and familial predisposition for migraine. In our study, MO patients received continuous intravenous infusion of α-CGRP (n = 40) and PACAP38 (n = 32) for 20 minutes. Premonitory and nonheadache symptoms were recorded by a self-administered questionnaire. Information on familial predisposition was obtained by telephone interview of first-degree relatives using a validated semistructured questionnaire. Twenty-five of 40 patients (63%) developed a migraine-like attack after CGRP infusion and 23 of 32 patients (72%) developed an attack after PACAP38 infusion. Only 2 patients (9%) with a CGRP-induced migraine-like attack reported PS, whereas 11 patients (48%) reported PS after PACAP38. Patients who developed a migraine-like attack did not report more PS than did patients with no attack after CGRP (P = 0.519) or PACAP38 (P = 0.103). Additionally, we found no difference in PS between patients with familial predisposition of migraine (75%) and patients with no family predisposition (56%) (P = 0.101). In conclusion, CGRP did not induce PS, whereas PACAP38 induced PS in 48% of patients. However, CGRP and PACAP38 did not induce more PS in patients who developed an attack compared with those who did not develop an attack.

Original languageEnglish
JournalPain
Volume157
Issue number12
Pages (from-to)2773-2781
Number of pages9
ISSN0304-3959
DOIs
Publication statusPublished - Dec 2016

ID: 49696289